Explore the latest content from Journal of Medical Economics…
Most Read 2015. You can read the most popular articles published in 2015 from the entire Medicine & Health Science portfolio. View and download for free now.
#ReadMyResearch campaign. Ever wondered how popular an article is with media outlets or on social media? We are showcasing papers from our Medicine & Health Science journals with high Altmetric scores and impressive Facebook & Twitter downloads. Explore the articles for free today.
Increase the speed of publication at no added cost! Journal of Medical Economics is introducing new publication timelines and prices. Manuscripts now have the choice of two publication tracks at submission - FastTrack and RapidTrack. Publish in as little as 3 weeks with FastTrack at no added cost or in as little as 7 weeks with lower RapidTrack fees. Contact Tanya Stezhka with a pre-submission enquiry or submit your original research today!
Author Services: new look, new information just for you. Thinking about publishing your research in an academic journal but not sure how to choose where to publish, how to write your article, or what to expect from peer review or during production? To help you navigate through getting published, we’ve re-launched our Author Services website, with lots of new resources. From choosing a journal to how to measure the impact of your work, we guide you through the journal publishing process from initial idea to post-publication, plus every step in between.
Writing about medical economics? Cost-effective medical practice? Resource utilisation? Journal of Medical Economics invites you to submit your latest research. Your original research manuscript can take as little as 5-8 weeks submission to online publication (charges apply). Why not read the full Aims & Scope or contact Commissioning Editor Tanya Stezhka to find out more? | Submit your paper here.
Peruse the most popular papers from Journal of Medical Economics.
Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
- Annie Guérin, Medha Sasane, Jie Zhang, Kenneth W. Culver, Katherine Dea, Roy Nitulescu & Eric Qiong Wu
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- T. Lanitis, F. E. Cotté, A. F. Gaudin, I. Kachaner, T. Kongnakorn & I. Durand-Zaleski
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program
- Brahim K. Bookhart, Lloyd Haskell, Luke Bamber, Maria Wang, Jeff Schein & Samir H. Mody
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation
- Marc Evans, Phil McEwan & Volker Foos
Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
- John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland